The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness  by Moraitis, Andreas G. et al.
Journal of Steroid Biochemistry & Molecular Biology 165 (2017) 114–120Review
The role of glucocorticoid receptors in metabolic syndrome and
psychiatric illness
Andreas G. Moraitisa,*, Thaddeus Blocka,b, Dat Nguyena, Joseph K. Belanoffa,b,*
aCorcept Therapeutics, 149 Commonwealth, Menlo Park, CA, United States
bDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, United States
A R T I C L E I N F O
Article history:
Received 1 November 2015
Received in revised form 14 March 2016
Accepted 18 March 2016
Available online 18 March 2016
Keywords:
Glucocorticoid receptor
Polymorphism
Metabolic syndrome
Psychiatric disorders
A B S T R A C T
Glucocorticoids (GCs) are involved in a large number of the physiological changes associated with
metabolic syndrome and certain psychiatric illness. Although signiﬁcance is often given to the
concentration of GC, its biological action is determined by the activation of intracellular GC receptors
(GR). Genetic polymorphisms of the GR and the large array of GR related cofactors can directly or
indirectly affect the pathophysiology and evolution of these conditions. This review will discuss the
effects of GR mutations on metabolic syndrome and psychotic depression.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Glucocorticoids (GCs) play an integral role in a wide array of
physiological systems in the body, affecting lipid and glucose
metabolism, immunosuppressive and anti-inﬂammatory reac-
tions, growth, reproduction and brain function. The effects of
cortisol are largely mediated by the GC receptor (GR). In its
unbound form, GR resides in the cytoplasm as part of a large
multiprotein complex comprising of chaperones (hsp90, hsp70),
co-chaperones, and immunophilins (FK506-binding protein)
(Fig. 1) [1]. Upon binding with cortisol, conformational changes
occur, leading to the dissociation of GR from the multiprotein* Corresponding author.
E-mail address: Amoraitis@corcept.com (A.G. Moraitis).
http://dx.doi.org/10.1016/j.jsbmb.2016.03.023
0960-0760/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access articcomplex. GR-GR dimers are often formed. The activated, ligand
bound GR complex then translocate to the nucleus, where it
functions as a transcription factor to regulate gene expression by
binding at speciﬁc glucocorticoid response elements regulating
both transactivation or transrepression. The mechanism of trans-
activation of gene expression usually involves GR dimers, binding
with speciﬁc glucocorticoid response elements and activating gene
expression. The transrepression mechanism involves the activated
GR interacting with transcription factors, like AP-1 and NF-kB,
preventing them from binding to their target genes. This
interaction can sometime allow GR to indirectly regulate gene
expression The transrepression mechanism involves the activated
GR interacting with transcription factors, like AP-1 and NF-kB,
preventing them from binding to their target genes. This
interaction can sometime allow GR to regulate gene expression
indirectly in the absence of direct DNA binding [2,3].le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig.1. Glucocorticoid Receptors’ Role in the Regulation of Gene Transcription: Unbound glucocorticoids (GCs) diffuse through the cell membranes binding to GC receptors
(GR) residing in the cytoplasm as part of a large multiprotein complex comprising of chaperones (hsp90, hsp70) and immunophilins (FKBP5). The bioavailability of
endogenous GCs at the cellular level is limited by enzymatic metabolism (11b-HSD enzymes). The activated GR then translocates to the nucleus to modulate the gene
transcription process. Liganded GRs bind to four main types of GR-response elements (GREs): simple (+GRE), negative (nGRE), composite GREs (cGRE), and interactions
(tGRE). The regulation of both transactivation and transrepression is dictated by the type of GRE and its binding partners.
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The human GR gene (NR3C1) is located on chromosome 5 and
consists of 9 exons (Fig. 2). Variations in the transcription and
translation of the GR gene can lead to seemingly random actions of
cortisol. However, these variations are necessary to allows cells
and tissues to appropriately adapt to wide concentrations of GC. As
an example, alternative splicing of the GR precursor mRNA can give
rise to 5 GR protein subtypes- GRa,GRb, GRg, GR-A and GR-P. Eight
more receptor proteins are produced by alternative translation
initiation from GR mRNA [4,5]. The classic GRa isoform can
increase GC sensitivity while the GRb is transcriptionally inactive
and is responsible for GC resistance. In addition to the GR isoforms
generated by alternative initiation of translation or alternativesplicing, four novel receptor variants (GR NS-1, GR DL-1, GR-S1 and
GR-S1 (349A)) [6,7] with multiple amino acid replacements/
truncation and unknown functional role have also been discov-
ered. These generic variations may account for the diversity in
patient presentations and responses to GC.
2.1. The role of GR expression, degradation and trafﬁcking on
glucocorticoid cellular responsiveness
The ability of GC to provoke cellular response is dependent on
the GR expression, degradation, and translocation into the nucleus.
The intracellular concentration of GR varies greatly between
different cells and tissues and involves a complex combination of
regulatory feedback mechanisms at both the transcriptional and
Fig. 2. Nine Exons of the Glucocorticoid Receptors with Locations of Single Nucleotide Polymorphisms (SNP).
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protein and GR mRNA can either trigger an up-regulation or a
down-regulation of GR depending of the cell type and its current
stage of cellular development. Since the intensity of biological
response is proportional to the concentration of GR, the variation
in regulatory feedback mechanisms allow the cells to modulate
their sensitivity to GC [8].
However, binding to the GR can trigger a signiﬁcant and rapid
reduction in the half-life of the GR protein (18 h to 9 h) [9]. The
degradation of GR through the ubiquitin-proteasomes pathway
requires GR proteins to be covalently tagged with multiple
ubiquitin moieties [10]. The additions of ubiquitin to the GR
proteins are mediated by ubiquitin-activating enzymes (E1),
ubiquitin-conjugating enzymes (E2) and ubiquitin ligase enzymes
(E3).
The contributions of the ubiquitin enzymes to the GR
degradation process are enzyme speciﬁc and may or may not be
hormonally dependent. For example, in human breast cancer cell
lines, GR degradation is triggered by estrogen through the
induction of the E3HDM2 enzymes [11]. Conversely, in vitro
studies have suggested that overexpression of E3CHIP [12] can
resist hormone induced GR degradation and help restore GR. This
suggests that the balance of speciﬁc ubiquitin enzymes is
necessary in maintaining steady-state GR concentration.
To exert its biological action, the ligand bound GR has to
translocate into the nucleus. However, GR trafﬁcking from the
cytoplasm to the nucleus is bidirectional. The ability of the receptor
to translocate back and forth [13] is primarily regulated by proteins
that serve as cytoplasmic anchors (molecular chaperones, dynein,
and 14-3-3 proteins) [14,15]. Additionally, in vitro studies have also
shown that c-Jun N-terminal kinase (JNK), can enhance nuclear
expulsion of GR limiting its transactivation properties [16].The
inability of GR to translocate into the nucleus can result in cellular
resistance to GCs, as seen in patients with steroid-resistant or
steroid-dependent asthma [17].
3. Glucocorticoid receptor and metabolic syndrome
GCs acting through the GR regulate key enzymes of glucose
metabolism in the liver, skeletal muscle, adipose tissue and the
pancreas. In the liver, GCs regulate the expression of major
gluconeogenic enzymes such as phosphoenolpyruvate carboxyki-
nase, glucose-6-phosphatase and tyrosine aminotransferase. In
skeletal muscle, GCs play a major role in peripheral glucose
utilization by interfering with translocation of glucose transporter
type 4. In the pancreas, GCs provoke hyperglycemia by inhibiting
glucose-stimulated insulin secretion from b-cells. Metabolic
syndrome, an important risk factor for coronary artery disease,
is a compilation of multiple metabolic abnormalities such asinsulin resistance, hyperglycemia, dyslipidemia, obesity, and
hypertension. The resemblance of the symptoms and biochemical
ﬁndings between Cushing’s syndrome and metabolic syndrome
suggest that cortisol plays a central role in the pathogenesis and
the evolution of both of these medical conditions. The vast
majority of obese subjects have cortisol levels currently considered
to be in the normal range, indicating that cortisol might exert a
portion of its deleterious effects at the tissue level because of
abnormalities of the GR and the intracellular cortisol metabolism.
Therefore, mutations of the GR gene, interfering with the
sensitivity of the GR to cortisol may be responsible for its varying
effects in different individuals. For example, patients can develop
the phenotype typically seen in Cushing’s syndrome despite
normal or even low serum cortisol levels. This has been described
in the literature as “cortisol hyper-reactive syndrome”, “glucocor-
ticoid hypersensitivity syndrome”, and “normocortisolemic Cush-
ing’s syndrome.” [18] Cortisol hypersensitivity was conﬁrmed by
Iida et al. when they conducted an ex vivo study of the peripheral
tissues from a patient with the manifestations of Cushing’s
syndrome who had extremely low cortisol levels [19]. Patients
carrying polymorphisms associated with decreased receptor
sensitivity to cortisol, as described later in the manuscript, have
increased insulin sensitivity, lower BMI, waist circumference and
LDL. Although, those polymorphisms are associated with a
favorable metabolic proﬁle, an increased incidence of autoimmune
disorders is anticipated. However, studies failed to demonstrate an
association with autoimmune disorders but found an increased
rates of nasal Staph. Aureus [20]. Only the 9b polymorphism of the
GR gene was found to have a positive association with autoimmune
disorders but, despite the favorable effects of that variant on
cardiometabolic parameters, carriers were found to have increased
intima-media thickness and a three-fold increased rate of
cardiovascular disease most likely due to a chronic pro-inﬂamma-
tory state seen in those subjects as supported by the elevated levels
of IL-6 and hsCRP.
An association between GR gene mutations and the manifes-
tations of metabolic syndrome was ﬁrst reported in 1992 by
Weaver et al. who demonstrated that homozygous carriers of the
BclI variant of GR had elevated fasting insulin and HOMA insulin
resistance index [21]. Another study also found a statistically
signiﬁcant increase in body weight, BMI, abdominal obesity,
fasting plasma glucose, insulin, and HOMA among homozygous
carriers of the BclI variant [22].
GR BclI polymorphism was found in a familial linkage study of
obese (BMI > 27 kg/m2) sibling pairs and some variants were
associated with higher abdominal visceral adiposity [23]. In a
study of middle-aged men, the 4.5-kb BclI allele was associated
with elevated waist to hip ratio, BMI and abdominal sagittal
diameter [24]. However, this polymorphism did not demonstrate
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(age 18–40 years old) [25]. A study of identical twins showed that
the 2.3-kb homozygotes exhibit the greatest increase in body
weight, abdominal adiposity and plasma cholesterol in response to
overfeeding [26]. In a prospective study with a prolonged follow-
up period, women with the GR BclI polymorphism showed a
substantial increase in body weight, subcutaneous adiposity, and
total body fat mass [27].
Overnight 1-mg dexamethasone suppression testing (DST) of
the BclI polymorphism carriers found them to have lower cortisol
levels, suggesting an increased sensitivity to GCs with respect to
the transrepression effect of cortisol on the POMC gene of the
corticotroph pituitary cells [28]. The exact mechanism through
which the BclI polymorphism may alter GC effects has not been
determined. The BclI polymorphism does not involve a coding,
regulatory or splicing region of the GR gene. Most likely this
polymorphism is linked to other functionally important polymor-
phisms. Genotype analysis for the rs2918419 and BclI GR
polymorphisms in Caucasian men performed by Syed et al. found
no signiﬁcant differences in wild-type BclI (G/G) vs. variant (G/C or
C/C) genotype frequencies between subjects categorized by
presence or absence of the metabolic syndrome or components
of it. [29] In contrast, men who were homozygous or heterozygous
for the rs2918419 GR polymorphism had a higher prevalence of
insulin resistance and higher mean fasting insulin concentration
compared to the wild type carriers. Such association, however, was
not found in women, suggesting an integral role of sex hormones in
the clinical implications of that GR polymorphism. Interestingly,
analysis of the combined effect of rs2918419 and BclI polymor-
phisms showed that men with BclI variant alleles on a background
of rs2918419 wild-type alleles had the lowest fasting insulin
concentrations. Thus, carrying Bcl1 variant alleles alone without
rs2918419 variant alleles was not associated with elevated fasting
insulin concentrations. The presence of the rs2918419 variant was
necessary for the association of those two intron 2 GR polymor-
phisms with insulin resistance. No conclusions of the
rs2918419 alone on insulin resistance can be extracted from the
current study since all subjects with the rs2918419 variants were
carriers of the BclI variants, supporting the possibility of a locus in
linkage disequilibrium with the BclI restriction site contributing to
insulin resistance. With changes in cortisol levels, recent studies
support the associations of BclI polymorphism with alterations of
the HPA axis rather than altered anthropometric measurements,
metabolic derangements and body composition [30]. Similar HPA
axis alterations in association with GR and CBG gene polymor-
phisms, without signiﬁcant differences in adipose tissue distribu-
tion, were reported in a study of prepubertal obese children [31].
However, a trend for a higher percentage of fat mass was detected
in GR G/G carriers. As supported by other studies [32], carriage of
an extended intron 2 haplotype that includes the
rs2918419 polymorphism downstream of the BclI site is most
likely linked to hyperinsulinemia.
The opposite trend was observed in homozygous carrier of the
rare Tth111I allele, although the results did not reach statistical
signiﬁcance. Carriers of the Tth111I variant showed elevated basal
cortisol secretion and bedtime levels of salivary cortisol [33].
Evidence of partial linkage to the ER22/23EK polymorphism is
associated with decreased glucocorticoid sensitivity [34].
Another well studied polymorphism of the GR gene is the
N363S variant, which is located in codon 363 of exon 2. It results
from an AAT ! AGT nucleotide change. This polymorphism results
in substitution of asparagine by serine. Although in vitro testing of
this GR polymorphism did not show any changes in its trans-
activating capacity [35,36], increased sensitivity to GCs was found
in vivo [37]. Russcher et al. reported a signiﬁcant increase in
transactivation of the GC response element luciferase reportergene by the N363S variant constructed GR [38]. However, another
group failed to replicate those ﬁndings but showed that in the
presence and absence of dexamethasone, the N363S variant can
regulate a novel set of genes compared to the wild-type GR [39].
The overnight 1-mg DST, showed no differences between N363S
carriers and controls, but there was a signiﬁcantly higher insulin
response in N363S carriers. Using a lower dexamethasone dosage
(0.25 mg) for the overnight DST, a signiﬁcantly larger cortisol
suppression and higher insulin response was noted in N363S
carriers without differences to the number of GR or the ligand
binding afﬁnity. With respect to anthropometric measurements, a
signiﬁcantly higher BMI was seen in N363S carriers compared to
non-carriers indicating a strong association between the N363S
variant and obesity. However, larger studies have demonstrated
conﬂicting results. A study of 491 UK Caucasian subjects found the
frequency of the G allele was equal among subjects with
BMI < 25 kg/m2 and BMI > 25 kg/m2 [40], suggesting that the
1220A > G GR variant is not associated with anthropometric
parameters. No association of the A-to-G point variation in exon
2 of the GR gene with obesity or cardiometabolic parameters was
found in 3 subsequent studies [21,41,42]. The association between
the 1220A > G polymorphism in exon 2 and obesity was further
hampered by contradictory results, although the majority of
reports were negative. Subsequent studies, in which a signiﬁcantly
higher mean value of BMI was found in heterozygotes for the
1220A > G polymorphism, using a different statistical analysis,
(2  2 tables), found that the relative risk for obesity in the
1220A > G carriers was not signiﬁcantly increased [43]. This
inconsistency may reﬂect the importance of publication bias
and over-interpretation of marginal ﬁndings.
In contrast to the above mentioned GR polymorphisms
associated with increased sensitivity to GCs, GR polymorphisms
associated with GC resistance have been studied. The most
important ones to date include the ER22/23EK (rs6189 and
rs6190) and the GR-9b (rs6198).
The ER22/23EK polymorphism is located in the transactivation
domain of the GR gene. A single nucleotide polymorphisms (SNPs)
has been identiﬁed in both of the two adjacent codons (22 and 23).
These SNPs are fully linked and are associated with relative GC
resistance[32,44]. Although no associations with body mass index
or fat mass has been found, the lean body mass was signiﬁcantly
higher in male carriers of the ER22/23EK polymorphism [45].
Increased muscle strength was also found in those men. In women,
no statistically signiﬁcant differences in BMI were found but a
smaller waist circumference was observed in ER22/23EK carriers.
Another striking anthropometric difference that has been observed
in several studies between carriers and non-carriers of the ER22/
23EK polymorphism is that male ER233/23EK carriers were found
to be taller than non-carriers. Male ER22/23EK carriers were also
found to have increased insulin sensitivity, lower fasting insulin
levels, lower C-reactive protein and lower total and LDL cholesterol
levels [46].
Finally, the 9b polymorphism of the GR Gene has not been
linked with BMI, adipose mass changes, waist to hip ratio, insulin
sensitivity, LDL and HDL cholesterol levels. Although no signiﬁcant
differences were observed in anthropometric characteristics,
subjects homozygous for the 9b variant had increased intima
media thickness and an almost three fold increased risk for
cardiovascular disease, most likely due to a subtle but chronic pro-
inﬂammatory state [47].
This 9b polymorphism results in an increased expression and
stabilization of GRb which functions as an active inhibitor of the
active form, GRa [48]. Although the transactivation of the GR is not
affected by the 9b polymorphism, transrepression is signiﬁcantly
reduced, and a pro-inﬂammatory state is expected-due to a more
active immune system- in the 9b carriers [49].
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The deleterious psychiatric effects of chronic increased GR
stimulation due to excess exogenous or endogenous GCs have been
studied extensively. Even in patients administered short term GC
therapy, symptoms of hypomania, depression, and even psychosis
have been observed.
It has long been hypothesized that the development of
psychotic symptoms in Psychotic Depression (PD) is related to
increased or dysregulated systemic cortisol levels, leading to
increased dopamine levels and changes to dopamine metabolism,
which potentially induce psychotic symptoms in susceptible
individuals [50]. Biologic ﬁndings in patients with PD related to
elevated and dysregulated cortisol levels include high rates of non-
suppression on the DST [51], reduced diurnal ﬂuctuation of
cortisol, high plasma cortisol and ACTH levels, and increased
excretion of 24 h urinary free cortisol [52,53].
The mRNA expression of the GRa is reduced in lymphocytes of
patients with major depressive disorder, both while they are
depressed and when their depression is in remission. The same
pattern of reduced GRa mRNA is found in ﬁrst-degree relatives of
patients with bipolar disorder. Those HPA axis abnormalities, at
least at the GR level, could represent a trait marker for mood
disorders [54]. Patients with depression and history of childhood
abuse have enhanced HPA axis responses to psychosocial stress
[55] and blunted adrenocorticotropin and cortisol response to low-
dose dexamethasone. Those ﬁndings were not present in the non-
depressed patients with a history of childhood abuse [56]. Cortisol
responses to dexamethasone/CRH challenge in healthy subjects
with high genetic load for affective disorders lies between the
responses of healthy subjects without a family history of
depression and those of depressed patients suggesting that genetic
vulnerability may be intertwined with early life experience to
produce to the ﬁnal expression of the disease [57,58].
All carriers of the ER22/23EK polymorphism carry the TthIIII
minor allele and demonstrate reduced GC sensitivity. An increased
risk of developing depression has been reported in subjects with
smaller hippocampal size which is more prevalent in homozygous
carriers of the TthIIII polymorphism [59,60]. The observation of
smaller hippocampal volumes in TthIIII polymorphism carriers
suggests a link between the TthIII I polymorphism and unipolar
depression. Conversely, a lower prevalence of heterozygous TthIII I
polymorphism carriers was found in bipolar disorder patients [61].
This may suggest a trend towards a protective effect on the clinical
manifestations and course of bipolar disorder in TthIIII polymor-
phism carriers [55].
The role of the ER22/23EK variant which is associated with
relative resistance to GC, as shown by a reduction of transactivating
capacity in vitro and less suppression of cortisol levels after 1 mg
DST in vivo. Relative GC resistance associated with the ER22/23EK
polymorphism might protect from the development of dementia
or cognitive decline with aging. Dementia and white matter lesions
were less frequent in older (over 55 years) carriers of the ER22/
23EK variant [62]. In addition, carriers of the ER22/23EK variant
had better cognitive speed tasks and less progression of subcortical
lesions.
In a study of patients with depression, carrier of the ER22/23EK
polymorphism had higher rates of recurrent major depression
episodes and responded faster to treatment with antidepressants
[63,64]. A possible explanation could be the higher concentration
of the less active GR variant which could lead to GC resistance [65].
An association between the BclI polymorphism and major
depression has been found in several studies. This variant is
associated with increased sensitivity to GC. The frequency of the
BclI variant was higher in patients with major depression andcarriers were found to have higher ACTH levels and a worse
response to antidepressant therapy [59,66].
The 9b polymorphism of the GR gene has been linked with a
lower incidence of bipolar disorder compared to healthy subjects.
A higher incidence of the 9b polymorphism has been linked with a
lower frequency of hypomanic episodes in patients with bipolar
disorder, suggesting a protective effect of this polymorphism [67].
As mentioned before, this variation results in increased expression
and stability of GRb, functioning as a dominant negative inhibitor
of the active receptor GRa.
The role of FKBP5, an important factor that controls GR sensitivity
and signaling, has been increasingly recognized. The FKBP5 is a
HSP90 co-chaperone that binds to GR in the cytosol and decreases
the afﬁnity of the GR for its ligand as well as the probability of the
translocation of the GR-ligand complex into the nucleus. FKBP5 SNPs
have been linked to a variety of psychiatric disorders including
dissociative symptoms after trauma, a predictor of PTSD develop-
ment in children and adult [68]. In addition, FKBP5 SNPs have been
linked to recurrence of major depression and the response to
antidepressants. The rs9296158 SNP has been found to be associated
with a signiﬁcant risk for PTSD development in subjects traumatized
as children. The mechanism by which FKBP5 SNPs alter the function
of the HPA axis in PTSD patients is by selectively changing cellular
expression of FKBP5 and sensitivity of GR signaling. The reduction of
STAT5B mRNA levelsfoundinblood cells fromPTSDpatientscarrying
the rs9296158 SNP provides another mechanism of altered GR
sensitivity [69]. Docking of the GR to a binding site on the STAT5B N-
terminus inhibits GR nuclear translocation. Thereby, STAT5B
deﬁciency could induce excessive GR signal transduction and GR-
mediated transcription of target genes.
Understanding that polymorphisms of the GR can lead to
variable effects on psychiatric diseases, several studies have set out
to evaluate a potent antagonist of GR, mifepristone, for the
reduction of the psychotic symptoms of psychotic depression
[70,71]. A consistent observation from these studies reveal that 7-
day administration of mifepristone appears to be effective in
reducing psychotic symptoms but only when sufﬁcient plasma
levels of mifepristone are reached. Because there is signiﬁcant
inter-individual variability in plasma mifepristone levels due to
complex pharmacokinetics, not every patient can achieve thera-
peutic mifepristone plasma level at a speciﬁc dose level of
mifepristone. While approximately 50% of patients administered
mifepristone 600 mg daily for 7 days will achieve this plasma
threshold after 7 days, approximately 66% of the patients will
surpass the threshold with dosing of 1200 mg for 7 days [72]. Both
dosing regimens appear to be safe and well tolerated. Of note, there
is also a relationship between increases in cortisol and ACTH levels
after seven days of dosing and response. While mifepristone
plasma levels are a predictor of response, cortisol and ACTH levels
are a mediator of response to treatment (publication in press),
signifying a biologically targeted therapy for the HPA dysregulation
of PD.
5. Summary
The role and activity of the GR, which mediates the ﬁnal step of
cortisol action at the cellular level, is the major determinant of
cortisol’s effects. Polymorphisms of the GR locus associated with
either increased sensitivity or resistance to GCs have been linked
to metabolic syndrome and psychiatric diseases. Genetic abnor-
malities in proteins associated with the activity and eventual gene
products of the GR can further modulate the function of the
receptor leading to either resistance or increased sensitivity to
GCs. Further studies, assessing the GR itself along with other
factors inﬂuencing its function, are needed to investigate the
A.G. Moraitis et al. / Journal of Steroid Biochemistry & Molecular Biology 165 (2017) 114–120 119complex but crucial role of GR in metabolic diseases and
psychiatric illness.
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